Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive and debilitating diseases characterized by gradual obstruction of the pulmonary vasculature, leading to elevated pulmonary artery pressure (PAP) and increased pulmonary vascular resistance (PVR). If untreated, they can result in death due to right-sided heart failure. Riociguat is a novel soluble guanylate cyclase (sGC) stimulator that is approved for the treatment of PAH and CTEPH. We describe in detail the role of the nitric oxide-sGC-cyclic guanosine monophosphate (cGMP) signaling pathway in the pathogenesis of PAH and CTEPH and the mode of action of riociguat. We also review the preclinical data associated with the development of riociguat, along with the efficacy and safety data of riociguat from initial clinical trials and pivotal phase III randomized clinical trials in PAH and CTEPH. CHEST 2017; 151(2):468-480 KEY WORDS: chronic thromboembolic pulmonary hypertension; pulmonary arterial hypertension; sGC stimulator According to the current World Health Organization (WHO) classification, five categories of pulmonary hypertension (PH) exist: pulmonary arterial hypertension (PAH; group 1), PH resulting from left-sided heart disease (group 2), PH due to hypoxia or disorders of the respiratory system, or both (group 3), chronic thromboembolic ABBREVIATIONS: 6MWD = 6-minute walking distance; ADMA = asymmetric dimethylarginine; AE = adverse event; BH4 = tetrahydrobiopterin; BMPR-2 = bone morphogenetic protein receptor-2; cGMP = cyclic guanosine monophosphate; CHEST-1 and -2 = Chronic Thromboembolic Pulmonary Hypertension sGC-Stimulator Trial-1 and -2; CO = cardiac output; CTEPH = chronic thromboembolic pulmonary hypertension; eNOS = endothelial nitric oxide synthase; EQ-5D = EuroQol 5 Dimensions questionnaire; ERA = endothelin receptor antagonist; FC = functional class; HFpEF = heart failure with preserved ejection fraction; HR = heart rate; ILD = interstitial lung disease; LPH = Living with Pulmonary Hypertension questionnaire; LS = least squares; mPAP = mean pulmonary artery pressure; NADPH = nicotinamide adenine dinucleotide phosphate; NO = nitric oxide; NOS = nitric oxide synthase; NT-proBNP = N-terminal prohormone of brain natriuretic peptide; PAH = pulmonary arterial hypertension; PAP = pulmonary artery pressure; PATENT-1 and -2 = Pulmonary Arterial Hypertension sGC-Stimulator Trial-1 and -2; PDE5 = phosphodiesterase 5; PEA = pulmonary endarterectomy; PH = pulmonary hypertension; PH-sLVD = PH due to systolic left ventricular dysfunction; PKG = cGMP-dependent protein kinase; PVR = pulmonary vascular resistance; QoL = quality of life; RV = right ventricular; SAE = serious adverse event; sGC = soluble guanylate cyclase; sLVD = systolic left ventricular dysfunction; SvO 2 = mixed venous oxygen saturation; SVR = systemic vascular resistance; WHO = World Health Organization
pulmonary hypertension (CTEPH; group 4), and PH with unclear/multifactorial mechanisms (group 5) ( Table 1) . [1] [2] [3] [4] PH is defined as a mean pulmonary artery pressure (PAP) $ 25 mm Hg. PAH and CTEPH are progressive pulmonary hypertensive diseases that usually lead to extensive pulmonary vascular remodeling, causing a marked increase in pulmonary vascular resistance (PVR) that leads to right ventricular (RV) overload and death when untreated. 5, 6 Endothelial dysfunction of the pulmonary vasculature plays a key role in the progression of PAH and is characterized by impaired production of vasodilators such as nitric oxide (NO) and prostacyclin, and overexpression of vasoconstrictors such as endothelin-1, leading to elevated vascular tone and promotion of vascular remodeling. 7 These observations have underpinned three therapeutic target pathways in PAH: the prostacyclin pathway (eg, prostanoids such as epoprostenol, iloprost, and treprostinil), the endothelin pathway (eg, endothelin receptor antagonists [ERAs] such as bosentan, ambrisentan, and macitentan), and the cyclic guanosine monophosphate (cGMP) degradation pathway (eg, phosphodiesterase-5 [PDE5] inhibitors such as sildenafil and tadalafil). 5, 6, 8 Despite the availability of numerous treatment options, mortality rates in patients with PAH remain high. [9] [10] [11] [12] [13] Pulmonary endarterectomy (PEA) is the gold standard treatment for CTEPH, as it is potentially curative, making CTEPH the only form of PH that is curable. 5, 6, 14, 15 However, 24% to 37% of patients with CTEPH are ineligible for PEA, and 17% to 35% experience persistent/ recurrent PH after PEA. [16] [17] [18] [19] [20] [21] [22] These patients are candidates for medical therapy. 5, 6 Balloon pulmonary angioplasty may also be considered in patients with CTEPH who are technically inoperable or have an unfavorable risk to benefit ratio for PEA. 5, 6 Riociguat, a soluble guanylate cyclase (sGC) stimulator, is approved for the treatment of both PAH and inoperable CTEPH or persistent/recurrent CTEPH after PEA. 5, 6 Riociguat adds sGC stimulation as a fourth therapeutic target in PAH. 8 We review the mode of action of riociguat, its clinical efficacy, and its safety in PAH and CTEPH.
The Role of the NO-sGC-cGMP Signaling Pathway in PH NO is a key regulator of flow-induced vasodilatation in the lung (Fig 1) . [23] [24] [25] [26] In the healthy lung, NO is produced by the vascular endothelium, airway, and alveolar epithelial cells and diffuses to the smooth muscle layer, where it binds to a prosthetic heme group on sGC. 23, 24 On binding with NO, sGC catalyzes the synthesis of the secondary messenger cGMP from guanosine triphosphate, 27 leading to activation of cGMP-dependent protein kinase (PKG), which acts through a variety of mechanisms to reduce intracellular calcium concentrations and inhibit smooth muscle cell contraction.
A reduction in endogenous NO levels has been observed in patients with PAH, CTEPH, and PH associated with COPD and interstitial lung disease (ILD). 23 Levels of 26 Promotional and commercial use of the material in print, digital or mobile device format is prohibited without permission from the publisher Wolters Kluwer Health. Please contact healthpermissions@wolterskluwer.com for further information.
oxidation of the L-arginine amino group. In the absence of adequate cofactors, or in the presence of substrate deficiency, NO synthesis by eNOS becomes uncoupled, leading to decreased synthesis of NO and increased production of reactive oxygen species, which contribute to vascular pathology. 25 Changes in NO-sGC-cGMP signaling have been implicated in the downstream effects of endothelial dysfunction on the pulmonary vasculature, including pulmonary artery smooth muscle cell proliferation, vasoconstriction, platelet aggregation and fibrosis, leukocyte recruitment, inflammation, maladaptive cardiac hypertrophy, and pulmonary vascular remodeling. [23] [24] [25] 41, 42 There is increasing interest in the role of genetic factors in PH. Mutations in genes coding for bone morphogenetic protein receptor-2 (BMPR-2) are the main cause of heritable PAH. 43 44 A mutation in the gene encoding caveolin-1 has also been associated with an increased risk of PAH developing. 45 Targeting sGC in PH: Mode of Action of Riociguat Previous attempts to target the NO-sGC-cGMP pathway have focused on preventing cGMP degradation by inhibiting PDE5, one of the primary enzymes responsible for cGMP degradation in the lung (Fig 1) . The PDE5 inhibitors sildenafil and tadalafil have been shown to improve 6-minute walking distance (6MWD), WHO functional class (WHO FC), and pulmonary hemodynamics in treatment-naïve patients with PAH. 5, 6, 46, 47 Sildenafil has also been shown to increase 6MWD, reduce PVR, and delay time to clinical worsening in patients who are already being treated with intravenous epoprostenol. 48 Similarly, tadalafil has been shown to increase functional capacity and delay clinical worsening when added to background ERA therapy. 49 Registry and long-term extension study data have shown that a proportion of patients with PAH may not respond to PDE5 inhibitors alone. 11, [50] [51] [52] It is possible that in some of these patients, lack of response is due in part to insufficient pulmonary cGMP production. In mice with decreased cGMP synthesis due to disrupted expression of natriuretic peptide receptor A, sildenafil was ineffective at preventing hypoxic PH. 53 Similarly, decreased NO synthesis may restrict the effectiveness of PDE5 inhibitors by reducing the pulmonary vascular cGMP levels. 23, 26, 54, 55 Results from the Ambrisentan To this end, recent efforts have centered on identifying pharmacologic agents that enhance sGC-induced cGMP synthesis directly. 50,58-60 sGC stimulators such as riociguat have a dual mode of action that enhances sGC response to endogenous NO and directly stimulates sGC independent of NO binding. In vitro studies have shown that riociguat increases the activity of sGC by up to 73-fold and acts in synergy with NO to increase sGC activity up to 112-fold. 54 Thus, these agents circumvent the need for endogenous NO production for their mode of action, increasing cGMP levels through a mechanism that is different from that of PDE5 inhibitors (Fig 2) . 23, 26, 54, 61 Riociguat: Preclinical Data
The vasodilatory effects of riociguat have been demonstrated in several preclinical models of hypertension. Riociguat relaxed isolated saphenous artery rings from normal and nitrate-resistant rabbits and also normalized blood pressure and improved survival in high-and low-renin rat models of hypertension. 62 Moreover, in a Dahl salt-sensitive rat model of malignant hypertension, riociguat attenuated systemic hypertension, systolic dysfunction, fibrotic tissue remodeling, and degenerative changes in myocardium and renal cortex. 63 The beneficial effects on other pathologic processes associated with PH have also been demonstrated in several preclinical studies. Administration of riociguat partially reversed PH, RV hypertrophy, and remodeling of lung vascular tissue in hypoxic mouse and monocrotalineinjected rat models. 54 Similarly, riociguat attenuated bleomycin-induced PH and RV hypertrophy in mice, and to a greater extent than sildenafil. Additionally, amelioration of pulmonary inflammation and fibrosis was observed with riociguat treatment in the same mouse journal.publications.chestnet.org model. 64 Furthermore, riociguat has been shown to prevent the development of PH, RV hypertrophy, and vascular remodeling compared with control subjects in a cigarette-smoke-induced mouse model of COPD and PH. 65 In a rat model of angioproliferative PAH induced by hypoxia and the vascular endothelial growth factor receptor antagonist SU5416, riociguat treatment increased the open to occluded artery ratio, decreased the neointima to media ratio, reduced RV systolic pressure, and increased cardiac output (CO). Moreover, there was a greater decrease in RV hypertrophy and an increase in RV function than observed following treatment with sildenafil. 66 The antifibrotic effects of riociguat have also been demonstrated in three separate mouse models of fibrosis. Riociguat reduced skin thickening, myofibroblast differentiation, and collagen accumulation in the tight skin (TSK-1) and bleomycin-induced models of skin fibrosis in a dose-dependent manner, and in a sclerodermatous chronic graft-vs-host disease model of systemic sclerosis, riociguat ameliorated GI tract fibrosis to a greater extent than sildenafil. 67 The preclinical results observed with riociguat led to it becoming the first sGC stimulator to enter clinical development. In a single-dose, proof-of-concept study in 19 patients with PH (including patients with PAH, CTEPH, and PH with mild to moderate ILD), riociguat reduced mean PAP (mPAP) and PVR, and increased cardiac index. Riociguat had no effect on gas exchange or ventilationperfusion matching and was well tolerated. 68 In an open-label, 12-week, phase II study that included 33 patients with PAH and 42 patients with CTEPH, riociguat significantly improved 6MWD, cardiac index, mPAP, PVR, and WHO FC at week 12 compared with baseline. 69 The results from the long-term extension to this study show that long-term riociguat treatment ; P < .001), CO (þ0.9 L/min; P < .001), and mPAP (-5 mm Hg; P < .001) Significant improvements in NT-proBNP (P < . ; P < .001), CO (þ0.9 L/min; P < .001), and mPAP (-4 mm Hg; P < .001) Significant improvements in NT-proBNP (P < ; 95% CI, 20-52; P < .001), N-terminal prohormone of brain natriuretic peptide (NT-proBNP) (-432 pg/mL; 95% CI, -782 to -82; P < .001), WHO FC (P ¼ .003), time to clinical worsening (P ¼ .005), and Borg dyspnea score (P ¼ .002). Several other hemodynamic parameters including CO (þ0.9 L/min; 95% CI, 0.7-1.2; P < .001), mPAP (-5 mm Hg; 95% CI, -6 to -2; P < .001), and mixed venous oxygen saturation (SvO 2 ) (þ5%; 95% CI, 3-7; P < .001) were also improved with riociguat vs placebo in PATENT-1. 78 There was also evidence that the beneficial effects of riociguat were reflected in patient quality of life (QoL ), with the change in LPH score reaching only nominal significance considering the hierarchical testing procedure. 76, 78 The effects of riociguat in PATENT-1 were similar in treatment-naïve patients and in patients receiving riociguat added to a background therapy of ERAs or non-intravenous prostanoids.
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In the PATENT-2 long-term extension study, 61 after 12 weeks, mean 6MWD AE SD had changed by þ52 AE 61 m in the former group receiving a maximum of 2.5 mg riociguat (n ¼ 218) and by þ52 AE 67 m in the former placebo group following transition to riociguat (n ¼ 103). At the same 12-week time point in PATENT-2, patients formerly receiving placebo showed a decrease in NT-proBNP levels similar to those of patients formerly receiving a maximum of 2.5 mg riociguat.
In PATENT-2, improvements in 6MWD, NT-proBNP, WHO FC, Borg dyspnea score, and QoL seen during PATENT-1 were sustained for at least 2 years; at 2 years (mean treatment duration 135 weeks) in the overall population, mean 6MWD AE SD had increased from PATENT-1 baseline by þ47 AE 85 m (n ¼ 296), and WHO FC had improved/stabilized/worsened compared with baseline in 33%/58%/9% (n ¼ 306). 61, 81 The estimated survival was 93% at 2 years.
61,81
Chronic Thromboembolic Pulmonary Hypertension sGC-Stimulator Trials CHEST-1 was a phase III study of riociguat in 261 patients with inoperable CTEPH or persistent/recurrent CTEPH after PEA. 76 After 16 weeks' treatment with riociguat journal.publications.chestnet.org (up to 2.5 mg tid), the primary end point of 6MWD increased by 46 m vs placebo (LS mean difference, 95% CI, 25-67; P < .001). Riociguat-treated patients also showed improvements across a range of clinically relevant secondary end points, including PVR (-246 dyn$s$cm -5 ; 95% CI, -303 to -190; P < .001), NT-proBNP (-444 pg/mL; 95% CI, -843 to -45; P < .001), and WHO FC (P ¼ .03). The effects of riociguat were consistent, although somewhat stronger, in patients with inoperable CTEPH compared with those with persistent/recurrent CTEPH after PEA. 76 Riociguat is the first pharmacologic therapy that has been shown to significantly improve both 6MWD and PVR in patients with inoperable CTEPH and in patients with recurrent/persistent CTEPH after PEA in a large randomized controlled trial.
In addition to PVR, other hemodynamic effects of riociguat in the CHEST-1 study were comparable with its effects in the PATENT-1 study; CO (þ0.9 L/min; 95% CI, 0.6-1.1; P < .001), mPAP (-5 mm Hg; 95% CI, -7 to -3; P < .001), and SvO 2 (þ4%; 95% CI, 1-6; P ¼ .001) were all improved without significant changes in heart rate. 76, 78 Nominally significant improvements in health-related QoL were also evident in the CHEST-1 study (EQ-5D score, þ0.13; 95% CI, 0.06-0.21; P < .001), suggesting that the improvements in exercise capacity, hemodynamics, NT-proBNP levels, and WHO FC were translated into patient QoL benefits.
In the CHEST-2 long-term extension study, 77 mean 6MWD AE SD had increased by þ61 AE 59 m after 12 weeks in the former riociguat group (n ¼ 145) and by þ51 AE 64 m in the former placebo group following transition to riociguat (n ¼ 75). Patients formerly receiving placebo showed a decrease in NT-proBNP levels similar to that in patients formerly receiving riociguat at the same time point.
In CHEST-2, improvements in 6MWD and WHO FC seen during CHEST-1 were sustained for at least 2 years; at 2 years (mean treatment duration, 127 weeks) in the overall population 6MWD AE SD had increased from CHEST-1 baseline by þ50 AE 68 m (n ¼ 162) and WHO FC was improved/stabilized/worsened in 39%/58%/3% of the overall population (n ¼ 170). 77, 82 Estimated survival was 93% at 2 years. 82 Clinical Safety of Riociguat in PAH and CTEPH Overall, riociguat was well tolerated in the clinical studies. 68, 69, 72, 75, 77, 78 The most common adverse events (AEs) were headache, dizziness, indigestion, peripheral edema, nausea, diarrhea, and vomiting.
In the 12-week PATENT-1 study, eight patients (3%) receiving riociguat in doses up to 2.5 mg tid withdrew because of AEs, whereas 33 of the patients (8%) who entered PATENT-2 withdrew because of AEs by the March 2013 cutoff (mean treatment duration, 95 weeks). 78, 81 In CHEST-1, four patients (2%) receiving riociguat withdrew because of AEs, whereas seven of the 237 patients (3%) who entered CHEST-2 had withdrawn because of AEs at the March 2013 cutoff (mean treatment duration, 83 weeks). 76, 77 There is an increased likelihood of bleeding in patients with PH, particularly among patients receiving anticoagulation therapy. 83 The total rate of bleeding was not increased with riociguat vs placebo in the CHEST-1 and PATENT-1 studies. 76, 78 In the randomized riociguat studies, respiratory tract bleeding was reported in 2% of patients treated with riociguat and in 1% of patients treated with placebo. Hemoptysis (reported as a serious adverse event [SAE]) was observed in three riociguattreated patients (2%) in CHEST-1 and in two riociguattreated patients (1%) in PATENT-1. In CHEST-2 at 1 year (n ¼ 237; mean treatment duration, 83 weeks), a further three patients (1%) experienced significant hemoptysis, and one patient (< 1%) experienced pulmonary hemorrhage. 77 At the same time point in PATENT-2, hemoptysis and pulmonary hemorrhage were reported as SAEs in seven (2%) and three (1%) patients, respectively (overall population n ¼ 396; mean treatment duration, 95 weeks). 61 The mechanism by which riociguat could influence the incidence of respiratory tract bleeding is unclear, although bronchial artery vasodilation might contribute.
In PATENT-1, SAEs of syncope occurred in three patients (1%) in the group receiving a maximum of 2.5 mg, all of which were considered study drug related, and in five patients (4%) in the placebo group, one of which was considered study drug related (1%). In CHEST-1, the SAE of syncope was experienced by four patients (2%) in the riociguat group, three cases of which (2%) were considered study drug related, and by three patients (3%) in the placebo group, one case of which (1%) was considered study drug related. At 1 year of both PATENT-2 and CHEST-2, 2% of patients had experienced study-drug-related syncope. 61, 77 Renal failure was rare in the CHEST or PATENT studies. 61, [76] [77] [78] Riociguat: Indication, Dosing, and Clinical Pharmacology
Riociguat is indicated for the management of PAH and inoperable CTEPH or persistent/recurrent CTEPH after PEA in adult patients. 5, 6, 84, 85 To avoid the risk of hypotension from the vasodilatory effect of riociguat on the systemic circulation, the oral dose is adjusted for the individual patient, guided by the signs and symptoms of hypotension. The usual starting dose is 1 mg tid for the first 2 weeks, and the dose is increased by 0.5 mg tid at 2-week intervals to a maximum of 2.5 mg tid based on tolerability (systolic blood pressure $ 95 mm Hg and no signs or symptoms of hypotension). Dose reduction should be considered any time the drug is not tolerated. During phase III studies, 75% of patients with PAH and 77% of those with CTEPH tolerated the maximum dose of 2.5 mg tid. 76, 78 Oral riociguat is rapidly absorbed, with maximum plasma concentrations occurring after about 1 to 1 1/2 hours and a terminal elimination half-life of approximately 12 hours in patients with PAH. 84, 85 The absolute bioavailability of riociguat is approximately 94%, and food intake has no clinically relevant effect on pharmacokinetics. 84, 85 Pharmacokinetic studies indicate that riociguat has no effect on platelet aggregation at clinically relevant concentrations 86, 87 and has no clinically relevant drug to drug interactions with warfarin. 86 Riociguat can be used in combination with ERAs or prostanoids, or both, as seen in the PATENT study. 61, 78 Concerns over pharmacodynamic interactions between riociguat and PDE5 inhibitors were supported by the results of the PATENT PLUS study. 71 In this 12-week phase II study, coadministration of riociguat and sildenafil resulted in changes in blood pressure similar to those of sildenafil plus placebo. However, in the longterm extension study, a high rate of discontinuation was observed because of hypotension, and there were three deaths (18%) (not considered study drug related by the investigator). The potentially unfavorable safety signals with sildenafil plus riociguat, and no evidence of a positive benefit to risk ratio, mean that concomitant administration of riociguat with PDE5 inhibitors is contraindicated, as is coadministration of riociguat with nitrates or NO donors. 84, 85 Positioning of Riociguat in PAH and CTEPH Therapy
The efficacy data obtained in patients with PAH in the PATENT-1 and PATENT-2 studies led to the recommendation of riociguat as a first-line treatment as well as an add-on to background bosentan therapy in the 2015 European Society of Cardiology/European Respiratory Society PH treatment guidelines. Additionally, riociguat is the only pharmacotherapy recommended in the 2015 guidelines for the treatment of patients with symptomatic CTEPH that is inoperable or persistent/ recurrent after surgery. 5, 6 The use of riociguat as first-line therapy in PAH gives the option of sequential combination therapy with an ERA or prostanoid to potentially augment the benefit experienced by patients. In PATENT-1, it was demonstrated that riociguat provided additional efficacy to that achieved with ongoing ERA therapy. Previous studies adding a PDE5 inhibitor to ERA therapy have either not met their primary end point or not shown additional benefit. [88] [89] [90] In PATENT-1, riociguat showed efficacy in both the primary end point and several secondary end points in patients who were treatment-naïve with respect to PAH-specific drugs. 61 75 PH associated with COPD (Table 2) , 74 and PH associated with idiopathic interstitial pneumonia. 97 
Conclusions
Inadequate signaling of the NO-cGMP pathway may play an important role in the pathogenesis of PAH. sGC stimulators such as riociguat offer a novel approach to enhancing NO-mediated cGMP synthesis for the treatment of PH (Fig 2) . Findings from the phase III CHEST and PATENT studies indicate that riociguat significantly improves exercise capacity and a range of secondary end points, including pulmonary hemodynamics, NT-proBNP levels, and WHO FC, in patients with inoperable CTEPH and persistent/ recurrent CTEPH after PEA and in PAH. Riociguat is effective in treatment-naïve patients with PAH and in those who are receiving ERAs or prostanoids, or both, and is the only approved medical therapy for inoperable or persistent/recurrent CTEPH.
Stimulating the NO-sGC-cGMP pathway is a promising approach for the treatment of PAH and CTEPH. Further studies are needed to identify which patients are most likely to respond favorably to sGC stimulation and to determine if patients who do not respond to PDE5 inhibitors or other medical therapies for PAH may respond to sGC stimulation.
